Aravive Inc (ARAV) USD0.0001
Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.